Abstract
Raltegravir is an HIV integrase inhibitor that is metabolized through glucuronidation by uridine diphosphate glucuronosyltransferase 1A1, and its use is anticipated in combination with atazanavir (a uridine diphosphate glucuronosyltransferase 1A1 inhibitor). Two pharmacokinetic studies of healthy subjects assessed the effect of multiple-dose atazanavir or ritonavir-boosted atazanavir on raltegravir levels in plasma. Atazanavir and atazanavir plus ritonavir modestly increase plasma levels of raltegravir.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Anti-HIV Agents / pharmacokinetics*
-
Atazanavir Sulfate
-
Double-Blind Method
-
Female
-
Humans
-
Male
-
Oligopeptides / administration & dosage
-
Oligopeptides / pharmacokinetics*
-
Organic Chemicals / administration & dosage
-
Organic Chemicals / pharmacokinetics*
-
Placebos / administration & dosage
-
Plasma / chemistry*
-
Pyridines / administration & dosage
-
Pyridines / pharmacokinetics*
-
Pyrrolidinones
-
Raltegravir Potassium
Substances
-
Anti-HIV Agents
-
Oligopeptides
-
Organic Chemicals
-
Placebos
-
Pyridines
-
Pyrrolidinones
-
Raltegravir Potassium
-
Atazanavir Sulfate